Liège, Belgium 5 July 2016 – Mithra Pharmaceuticals announces today that it obtained a new Marketing Authorisation for the commercialization of its product Tibelia® (bioequivalent of Livial® developed by Mithra) in Spain.
Share it
Latest news
Mithra reaches milestone in estetrol skin study
8 April 2024
Mithra updates on its ongoing monetization process
28 March 2024